Key Secondary Endpoint: Percentage of Pediatric Patients With A1C ≤6.5% at 30 Weeks<sup>1,2</sup>

Accordion title open

Show Description

Accordion title close

Close Description

Key Secondary Endpoint: Percentage of Pediatric Patients With A1C ≤6.5% at 30 Weeks^1,2

A bar chart showing the percentage of patients with A1C ≤6.5% at 30 weeks. 68% of patients taking Mounjaro 5 mg (n=32) reached an A1C of ≤6.5% at 30 weeks. 81% of patients taking Mounjaro 10 mg (n=33) reached an A1C of ≤6.5% at 30 weeks. 75% of patients in the pooled Mounjaro (5 mg and 10 mg) (n=65) treatment arm reached an A1C of ≤6.5% at 30 weeks. 28% of patients taking placebo (n=34) reached an A1C of ≤6.5% at 30 weeks.

Key Secondary Endpoint: Percentage of Pediatric Patients With A1C ≤6.5% at 30 Weeks1,2

Key Secondary Endpoint: Percentage of Pediatric Patients With A1C ≤6.5% at 30 Weeks^1,2